Q2 2023 Cantargia AB Earnings Call Transcript
¶-
Thank you so much. It's a pleasure to present Cantargia H1 report after what I believe has been a very strong period, as well as a very nice summer with a good news flow.
So to take you into the details then, starting out with significant events during or after this period or during the summer, we have presented new data both in pancreatic cancer, as well as non-small cell lung cancer, for our lead program, nadunolimab, and more specifically, it's been in chemotherapy combinations. And the presentations have been made at the two major cancer conferences, AACR and ASCO, and we're coming back to all these data. But in essence, they are certainly strong and have created lots of external interest and attention around our programs.
But based on these results, we're now also planning for a randomized controlled clinical Phase IIb trial in pancreatic cancer, where patients will get nadunolimab with chemotherapy or chemotherapy alone. And as we progress with the planning, there will be much more details around this trial.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
